@CarolineOvadia@MFMSperling@RichardBurwick@devindirk @icpsupport @ICPcare Agree 100%. My concern is for the physician who orders the labs as recommended by SMFM, but is not given guidance on their interpretation. Non-fasting bile acids of 12 -> weekly antenatal testing with consideration for delivery at 37-39 weeks? Elevated LFTs with normal BA?
My awesome cofellow @samibackley is running for SMFM associate member representative.Please if you receive an email, take a minute and vote for him. He is hardworking , ambitious ,fun and down to earth! Exactly what we need during this pandemic. #backleybeatscovid :)
Population-based cohort study finds the risk of maternal adverse outcomes vary by ethnicity among Asian women; Filipina and Pacific Islander women appear at increased risk. @StephenWagnerMD @jackie_parchem https://t.co/QYk1wn5lIK
Postpartum NSAID Use and Adverse Outcomes among Women with Hypertensive Disorders of Pregnancy: A Systematic Review and Meta-analysis
@hipstermfm
What a beast you are. https://t.co/erKT8wmv3c
1) BA >100 associated with adverse outcomes https://t.co/hCZ3cFKR5W
2) UDCA now with questionable association with changes in BA levels https://t.co/KUWkGC30aH and no improved outcomes
3) Reasonable to perform serial BA levels and deliver based on HIGHEST, not MOST RECENT level??
Lessons gleaned from this:
1.) high risk of recurrence in ICP (~70%)
2.) Serial lab assessment can be critical
3.) Optimal dx, surveillance and delivery timing for ICP unknown.
@ICPcare @mfmchauhan @MatthewBicocca @perinate1